View Financial HealthCaprihans India 배당 및 자사주 매입배당 기준 점검 0/6Caprihans India 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률-15.7%자사주 매입 수익률총 주주 수익률-15.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트공시 • Sep 09+ 1 more updateCaprihans India Limited Announces Not to Recommend Any Dividend for Financial Year 2019-20Caprihans India Limited announced that in order to conserve financial resources owing to ongoing COVID-19 pandemic, the Board has not recommended any dividend for financial year 2019-20.모든 업데이트 보기Recent updatesReported Earnings • May 26Full year 2026 earnings released: ₹32.08 loss per share (vs ₹46.26 loss in FY 2025)Full year 2026 results: ₹32.08 loss per share (improved from ₹46.26 loss in FY 2025). Revenue: ₹7.43b (flat on FY 2025). Net loss: ₹470.0m (loss narrowed 24% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Sanjeev Tole was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.6m).New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹883.6m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹883.6m market cap, or US$9.57m).Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹10.67 loss per share (vs ₹14.13 loss in 3Q 2025)Third quarter 2026 results: ₹10.67 loss per share (improved from ₹14.13 loss in 3Q 2025). Revenue: ₹1.78b (down 5.0% from 3Q 2025). Net loss: ₹156.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 13Second quarter 2026 earnings released: ₹17.02 loss per share (vs ₹21.59 loss in 2Q 2025)Second quarter 2026 results: ₹17.02 loss per share (improved from ₹21.59 loss in 2Q 2025). Revenue: ₹1.79b (down 5.1% from 2Q 2025). Net loss: ₹248.9m (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.공시 • Sep 01Caprihans India Limited, Annual General Meeting, Sep 23, 2025Caprihans India Limited, Annual General Meeting, Sep 23, 2025, at 12:00 Indian Standard Time.Reported Earnings • Aug 12First quarter 2026 earnings released: ₹9.27 loss per share (vs ₹13.41 loss in 1Q 2025)First quarter 2026 results: ₹9.27 loss per share (improved from ₹13.41 loss in 1Q 2025). Revenue: ₹1.85b (up 3.7% from 1Q 2025). Net loss: ₹135.6m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.공시 • Aug 04Caprihans India Limited to Report Q1, 2026 Results on Aug 11, 2025Caprihans India Limited announced that they will report Q1, 2026 results on Aug 11, 2025Reported Earnings • May 28Full year 2025 earnings released: ₹46.26 loss per share (vs ₹39.30 loss in FY 2024)Full year 2025 results: ₹46.26 loss per share (further deteriorated from ₹39.30 loss in FY 2024). Revenue: ₹7.68b (up 10% from FY 2024). Net loss: ₹621.8m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹2.12b market cap, or US$24.7m).Reported Earnings • Feb 12Third quarter 2025 earnings released: ₹14.13 loss per share (vs ₹10.39 loss in 3Q 2024)Third quarter 2025 results: ₹14.13 loss per share (further deteriorated from ₹10.39 loss in 3Q 2024). Revenue: ₹1.95b (up 21% from 3Q 2024). Net loss: ₹185.6m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.87b market cap, or US$22.1m).New Risk • Nov 12New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹2.16b market cap, or US$25.6m).공시 • Oct 15Caprihans India Limited announced that it expects to receive INR 240 million in funding from Bilcare Mauritius LimitedCaprihans India Limited announced a private placement of 4,800,000 for the gross proceeds of INR 50 per warrant for the gross proceeds of INR 240,000,000 on October 14, 2024. The warrants will be exercised at an exercise price of INR 150 per share. The warrants will be issued on preferential basis. The transaction will include participation from new investor, Bilcare Mauritius Limited. The transaction has been approved by the shareholders of the company.Board Change • Oct 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairperson, MD & President Ankita Kariya is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Sep 27Caprihans India Limited Approves Appointment of Kavaseri R Viswanathan as A Non-Executive, Independent DirectorCaprihans India Limited approved Appointment of Mr. Kavaseri R Viswanathan as a Non-Executive, Independent Director of the Company for a term of five years effective from September 04, 2024 to September 03, 2029.공시 • Sep 25Caprihans India Limited Announces Cessation of Board of DirectorsCaprihans India Limited announced that Mr. Siddharth Shyam Shetye and Mr. Nitin Joshi, who served as an Independent Directors of the company from September 26, 2019 has concluded their tenure as an Independent Directors on the Board of the Company respectively. Their term officially ended from the close of business hours on September 25, 2024, following completion of their second term. Reason for change: Cessation of directorship due to completion of Second term as an Independent Director from the closing hours of September 25, 2024.공시 • Sep 06Caprihans India Limited, Annual General Meeting, Sep 26, 2024Caprihans India Limited, Annual General Meeting, Sep 26, 2024.공시 • Sep 04+ 2 more updatesCaprihans India Limited to Report Q2, 2025 Results on Nov 14, 2024Caprihans India Limited announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 13First quarter 2025 earnings released: ₹13.41 loss per share (vs ₹8.13 loss in 1Q 2024)First quarter 2025 results: ₹13.41 loss per share (further deteriorated from ₹8.13 loss in 1Q 2024). Revenue: ₹1.86b (up 10% from 1Q 2024). Net loss: ₹176.1m (loss widened 65% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.공시 • Aug 05Caprihans India Limited to Report Q1, 2025 Results on Aug 12, 2024Caprihans India Limited announced that they will report Q1, 2025 results on Aug 12, 2024Reported Earnings • May 28Full year 2024 earnings released: ₹39.31 loss per share (vs ₹54.64 profit in FY 2023)Full year 2024 results: ₹39.31 loss per share (down from ₹54.64 profit in FY 2023). Revenue: ₹7.22b (down 22% from FY 2023). Net loss: ₹516.2m (down 172% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 11% per year.New Risk • Mar 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹2.18b market cap, or US$26.0m).Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹144, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.Reported Earnings • Feb 11Third quarter 2024 earnings released: ₹10.39 loss per share (vs ₹0.71 loss in 3Q 2023)Third quarter 2024 results: ₹10.39 loss per share (further deteriorated from ₹0.71 loss in 3Q 2023). Revenue: ₹1.67b (up 100% from 3Q 2023). Net loss: ₹136.4m (loss widened ₹127.0m from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹2.78b market cap, or US$33.4m).Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹235, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 173% over the past three years.공시 • Sep 09+ 3 more updatesCaprihans India Limited to Report Q2, 2024 Results on Nov 14, 2023Caprihans India Limited announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 12First quarter 2024 earnings released: ₹8.13 loss per share (vs ₹1.18 profit in 1Q 2023)First quarter 2024 results: ₹8.13 loss per share (down from ₹1.18 profit in 1Q 2023). Revenue: ₹1.76b (up 60% from 1Q 2023). Net loss: ₹106.7m (down ₹122.1m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.공시 • Aug 04Caprihans India Limited to Report Q1, 2024 Results on Aug 11, 2023Caprihans India Limited announced that they will report Q1, 2024 results on Aug 11, 2023New Risk • Jul 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹3.01b market cap, or US$36.7m).Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹227, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 368% over the past three years.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 273% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹164, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 222% over the past three years.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹130, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years.공시 • May 19Caprihans India Limited to Report Fiscal Year 2023 Results on May 26, 2023Caprihans India Limited announced that they will report fiscal year 2023 results on May 26, 2023Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹121, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 254% over the past three years.Reported Earnings • Feb 08Third quarter 2023 earnings released: ₹0.71 loss per share (vs ₹3.84 profit in 3Q 2022)Third quarter 2023 results: ₹0.71 loss per share (down from ₹3.84 profit in 3Q 2022). Revenue: ₹854.0m (down 14% from 3Q 2022). Net loss: ₹9.35m (down 119% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 02Caprihans India Limited to Report Q3, 2023 Results on Feb 07, 2023Caprihans India Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Feb 07, 2023공시 • Dec 29Caprihans India Limited Approves Executive ChangesThe board of directors of Caprihans India Limited at meeting held on December 28, 2022, approved the appointment of Mr. Sudhir Pendse as Non-Executive Independent Director (Additional Director) of the company to hold such office with effect from December 28, 2022 upto the date of the upcoming Annual/Extra Ordinary General Meeting of the Company. Mr. Pendse is a Commerce Graduate with Diploma in Exim Policies and Procedure . He also holds diploma in French language He has more than 30 years of experience in the field of Export Import, Exim logistics etc.; The company approved the resignation of Mr. Narendra Kumar Lodha as Non- Executive Non Independent Director with effect immediate effect., resignation of Mr. Chandrashekhar Joglekar as Non- Executive Non Independent Director of the Company with immediate effect.; resignation of Mr. Tanuj Kumar Lodha as Non- Executive Independent Director of the Company with immediate effect due to prior engagement and continuous travel.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 212% over the past three years.Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: ₹4.35 (vs ₹1.43 in 2Q 2022)Second quarter 2023 results: EPS: ₹4.35 (up from ₹1.43 in 2Q 2022). Revenue: ₹935.8m (flat on 2Q 2022). Net income: ₹57.2m (up 204% from 2Q 2022). Profit margin: 6.1% (up from 2.0% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹163, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 263% over the past three years.공시 • Oct 30Caprihans India Limited to Report Q2, 2023 Results on Nov 05, 2022Caprihans India Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 05, 2022공시 • Oct 20Caprihans India Limited Announces Change in DirectorateCaprihans India Limited announced Resignation of Mr. Robin Banerjee, Managing Director: Mr. Robin Banerjee has resigned from position of the Managing Director of the Company vide his letter dated October 18, 2022 with effect from October 19, 2022. Mr. Shreyans Mohan Bhandari is appointed as Non-Executive Non-Independent Director of the Company to hold such office with effect from October 19, 2022 upto the date of the ensuing Annual/Extra Ordinary General Meeting of the Company.Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non- Executive Independent Director Tanuj Lodha was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 11Caprihans India Limited Appoints Tanuj Lodha as A Non- Executive IndependentCaprihans India Limited appointed Tanuj Lodha as a Non- Executive Independent for period of 5 years with effect from May 03, 2022 upto May 02, 2027 at its AGM held on August 10, 2022. Mr. Tanuj Lodha aged 42, is an Advocate by profession and is a Senior Partner at Lodha & Lodha Advocates. Mr. Lodha is a Bachelor of Law (LLB), Chartered Accountant, MBA finance & marketing from the Indian School of Business. Mr. Lodha specializes in commercial laws including Arbitration, IBC, Real Estate & Company Laws. Mr. Lodha has represented several Corporates and other Persons in important matters and has appeared in several reported judgements' 'Mr. Lodha is an avid Golfer and actively participates in charitable causes.공시 • Jul 28Caprihans India Limited to Report Q1, 2023 Results on Aug 05, 2022Caprihans India Limited announced that they will report Q1, 2023 results on Aug 05, 2022Reported Earnings • Jul 20Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.93b (up 33% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year whereas the company’s share price has increased by 56% per year.공시 • Jul 19Caprihans India Limited, Annual General Meeting, Aug 10, 2022Caprihans India Limited, Annual General Meeting, Aug 10, 2022, at 11:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022; to appoint a Director in place of Mr. Chandrashekhar Joglekar (DIN: 07265143); to appoint Mr. Tanuj Kumar Lodha (DIN: 06874388) as a Non-Executive, Independent Director of the Company; to ratify remuneration of Cost Auditors; and to reappoint Mr. Robin Banerjee (DIN 00008893) as Managing Director and payment of remuneration.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 148% over the past three years.Reported Earnings • May 15Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.97b (up 35% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.2% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.공시 • May 07Caprihans India Limited to Report Fiscal Year 2022 Results on May 12, 2022Caprihans India Limited announced that they will report fiscal year 2022 results on May 12, 2022Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹136, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 132% over the past three years.공시 • Mar 30Caprihans India Limited Announces Resignation of Anjali Seth as Independent DirectorCaprihans India Limited announced that Ms. Anjali Seth (DIN: 05234352), Independent Director, vide letter dated March 29, 2022, has tendered her resignation from the Board of the Company.Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.84 (down from ₹4.31 in 3Q 2021). Revenue: ₹1.00b (up 38% from 3Q 2021). Net income: ₹50.4m (down 11% from 3Q 2021). Profit margin: 5.0% (down from 7.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.공시 • Feb 03Caprihans India Limited to Report Q3, 2022 Results on Feb 10, 2022Caprihans India Limited announced that they will report Q3, 2022 results on Feb 10, 2022Board Change • Jan 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years.Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS ₹1.43 (vs ₹3.71 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹943.3m (up 23% from 2Q 2021). Net income: ₹18.8m (down 61% from 2Q 2021). Profit margin: 2.0% (down from 6.3% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹151, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 95% over the past three years.Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹3.83 (vs ₹1.77 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹851.6m (up 49% from 1Q 2021). Net income: ₹50.3m (up 117% from 1Q 2021). Profit margin: 5.9% (up from 4.1% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹15.40 (vs ₹7.00 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.04b (up 5.6% from FY 2020). Net income: ₹202.2m (up 120% from FY 2020). Profit margin: 6.6% (up from 3.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.Valuation Update With 7 Day Price Move • May 11Investor sentiment improved over the past weekAfter last week's 37% share price gain to ₹130, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 56% over the past three years.Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹93.00, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 8.1% over the past three years.공시 • Feb 04Caprihans India Limited to Report Q3, 2021 Results on Feb 10, 2021Caprihans India Limited announced that they will report Q3, 2021 results on Feb 10, 2021공시 • Jan 22Caprihans India Limited Announces Sad Demise of K.V. Mani, Independent Director of the CompanyCaprihans India Limited announced the sad demise of Mr. K.V. Mani (DIN: 00533148), Independent Director of the Company on the night of January 20, 2021.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹87.30, the stock is trading at a trailing P/E ratio of 8.4x, up from the previous P/E ratio of 7x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 23%.Is New 90 Day High Low • Dec 28New 90-day high: ₹84.40The company is up 56% from its price of ₹54.15 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.Is New 90 Day High Low • Dec 08New 90-day high: ₹81.15The company is up 51% from its price of ₹53.75 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period.Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 16% share price gain to ₹76.15, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.3x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.Valuation Update With 7 Day Price Move • Nov 17Market bids up stock over the past weekAfter last week's 18% share price gain to ₹75.45, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS ₹3.71The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹819.3m (up 5.8% from 2Q 2020). Net income: ₹48.7m (up 205% from 2Q 2020). Profit margin: 5.9% (up from 2.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 09New 90-day high: ₹66.80The company is up 27% from its price of ₹52.50 on 11 August 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.공시 • Sep 09+ 1 more updateCaprihans India Limited Announces Not to Recommend Any Dividend for Financial Year 2019-20Caprihans India Limited announced that in order to conserve financial resources owing to ongoing COVID-19 pandemic, the Board has not recommended any dividend for financial year 2019-20.공시 • Aug 09Caprihans India Limited to Report Q1, 2021 Results on Aug 12, 2020Caprihans India Limited announced that they will report Q1, 2021 results on Aug 12, 2020공시 • Jun 17Caprihans India Limited to Report Fiscal Year 2020 Results on Jun 19, 2020Caprihans India Limited announced that they will report fiscal year 2020 results on Jun 19, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 509486 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 509486 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Caprihans India 배당 수익률 vs 시장509486의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (509486)0%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Chemicals)0.8%분석가 예측 (509486) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 509486 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 509486 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 509486 Indian 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: 509486 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/13 04:33종가2026/06/12 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Caprihans India Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Naveed MD.FirstCall Research
공시 • Sep 09+ 1 more updateCaprihans India Limited Announces Not to Recommend Any Dividend for Financial Year 2019-20Caprihans India Limited announced that in order to conserve financial resources owing to ongoing COVID-19 pandemic, the Board has not recommended any dividend for financial year 2019-20.
Reported Earnings • May 26Full year 2026 earnings released: ₹32.08 loss per share (vs ₹46.26 loss in FY 2025)Full year 2026 results: ₹32.08 loss per share (improved from ₹46.26 loss in FY 2025). Revenue: ₹7.43b (flat on FY 2025). Net loss: ₹470.0m (loss narrowed 24% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Sanjeev Tole was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.6m).
New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹883.6m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹883.6m market cap, or US$9.57m).
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹10.67 loss per share (vs ₹14.13 loss in 3Q 2025)Third quarter 2026 results: ₹10.67 loss per share (improved from ₹14.13 loss in 3Q 2025). Revenue: ₹1.78b (down 5.0% from 3Q 2025). Net loss: ₹156.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 13Second quarter 2026 earnings released: ₹17.02 loss per share (vs ₹21.59 loss in 2Q 2025)Second quarter 2026 results: ₹17.02 loss per share (improved from ₹21.59 loss in 2Q 2025). Revenue: ₹1.79b (down 5.1% from 2Q 2025). Net loss: ₹248.9m (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
공시 • Sep 01Caprihans India Limited, Annual General Meeting, Sep 23, 2025Caprihans India Limited, Annual General Meeting, Sep 23, 2025, at 12:00 Indian Standard Time.
Reported Earnings • Aug 12First quarter 2026 earnings released: ₹9.27 loss per share (vs ₹13.41 loss in 1Q 2025)First quarter 2026 results: ₹9.27 loss per share (improved from ₹13.41 loss in 1Q 2025). Revenue: ₹1.85b (up 3.7% from 1Q 2025). Net loss: ₹135.6m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
공시 • Aug 04Caprihans India Limited to Report Q1, 2026 Results on Aug 11, 2025Caprihans India Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Reported Earnings • May 28Full year 2025 earnings released: ₹46.26 loss per share (vs ₹39.30 loss in FY 2024)Full year 2025 results: ₹46.26 loss per share (further deteriorated from ₹39.30 loss in FY 2024). Revenue: ₹7.68b (up 10% from FY 2024). Net loss: ₹621.8m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹2.12b market cap, or US$24.7m).
Reported Earnings • Feb 12Third quarter 2025 earnings released: ₹14.13 loss per share (vs ₹10.39 loss in 3Q 2024)Third quarter 2025 results: ₹14.13 loss per share (further deteriorated from ₹10.39 loss in 3Q 2024). Revenue: ₹1.95b (up 21% from 3Q 2024). Net loss: ₹185.6m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.87b market cap, or US$22.1m).
New Risk • Nov 12New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹2.16b market cap, or US$25.6m).
공시 • Oct 15Caprihans India Limited announced that it expects to receive INR 240 million in funding from Bilcare Mauritius LimitedCaprihans India Limited announced a private placement of 4,800,000 for the gross proceeds of INR 50 per warrant for the gross proceeds of INR 240,000,000 on October 14, 2024. The warrants will be exercised at an exercise price of INR 150 per share. The warrants will be issued on preferential basis. The transaction will include participation from new investor, Bilcare Mauritius Limited. The transaction has been approved by the shareholders of the company.
Board Change • Oct 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairperson, MD & President Ankita Kariya is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Sep 27Caprihans India Limited Approves Appointment of Kavaseri R Viswanathan as A Non-Executive, Independent DirectorCaprihans India Limited approved Appointment of Mr. Kavaseri R Viswanathan as a Non-Executive, Independent Director of the Company for a term of five years effective from September 04, 2024 to September 03, 2029.
공시 • Sep 25Caprihans India Limited Announces Cessation of Board of DirectorsCaprihans India Limited announced that Mr. Siddharth Shyam Shetye and Mr. Nitin Joshi, who served as an Independent Directors of the company from September 26, 2019 has concluded their tenure as an Independent Directors on the Board of the Company respectively. Their term officially ended from the close of business hours on September 25, 2024, following completion of their second term. Reason for change: Cessation of directorship due to completion of Second term as an Independent Director from the closing hours of September 25, 2024.
공시 • Sep 06Caprihans India Limited, Annual General Meeting, Sep 26, 2024Caprihans India Limited, Annual General Meeting, Sep 26, 2024.
공시 • Sep 04+ 2 more updatesCaprihans India Limited to Report Q2, 2025 Results on Nov 14, 2024Caprihans India Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 13First quarter 2025 earnings released: ₹13.41 loss per share (vs ₹8.13 loss in 1Q 2024)First quarter 2025 results: ₹13.41 loss per share (further deteriorated from ₹8.13 loss in 1Q 2024). Revenue: ₹1.86b (up 10% from 1Q 2024). Net loss: ₹176.1m (loss widened 65% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
공시 • Aug 05Caprihans India Limited to Report Q1, 2025 Results on Aug 12, 2024Caprihans India Limited announced that they will report Q1, 2025 results on Aug 12, 2024
Reported Earnings • May 28Full year 2024 earnings released: ₹39.31 loss per share (vs ₹54.64 profit in FY 2023)Full year 2024 results: ₹39.31 loss per share (down from ₹54.64 profit in FY 2023). Revenue: ₹7.22b (down 22% from FY 2023). Net loss: ₹516.2m (down 172% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 11% per year.
New Risk • Mar 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹2.18b market cap, or US$26.0m).
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹144, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.
Reported Earnings • Feb 11Third quarter 2024 earnings released: ₹10.39 loss per share (vs ₹0.71 loss in 3Q 2023)Third quarter 2024 results: ₹10.39 loss per share (further deteriorated from ₹0.71 loss in 3Q 2023). Revenue: ₹1.67b (up 100% from 3Q 2023). Net loss: ₹136.4m (loss widened ₹127.0m from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.
New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹2.78b market cap, or US$33.4m).
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹235, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 173% over the past three years.
공시 • Sep 09+ 3 more updatesCaprihans India Limited to Report Q2, 2024 Results on Nov 14, 2023Caprihans India Limited announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 12First quarter 2024 earnings released: ₹8.13 loss per share (vs ₹1.18 profit in 1Q 2023)First quarter 2024 results: ₹8.13 loss per share (down from ₹1.18 profit in 1Q 2023). Revenue: ₹1.76b (up 60% from 1Q 2023). Net loss: ₹106.7m (down ₹122.1m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Aug 04Caprihans India Limited to Report Q1, 2024 Results on Aug 11, 2023Caprihans India Limited announced that they will report Q1, 2024 results on Aug 11, 2023
New Risk • Jul 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹3.01b market cap, or US$36.7m).
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹227, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 368% over the past three years.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 273% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹164, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 222% over the past three years.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹130, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years.
공시 • May 19Caprihans India Limited to Report Fiscal Year 2023 Results on May 26, 2023Caprihans India Limited announced that they will report fiscal year 2023 results on May 26, 2023
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹121, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 254% over the past three years.
Reported Earnings • Feb 08Third quarter 2023 earnings released: ₹0.71 loss per share (vs ₹3.84 profit in 3Q 2022)Third quarter 2023 results: ₹0.71 loss per share (down from ₹3.84 profit in 3Q 2022). Revenue: ₹854.0m (down 14% from 3Q 2022). Net loss: ₹9.35m (down 119% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 02Caprihans India Limited to Report Q3, 2023 Results on Feb 07, 2023Caprihans India Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Feb 07, 2023
공시 • Dec 29Caprihans India Limited Approves Executive ChangesThe board of directors of Caprihans India Limited at meeting held on December 28, 2022, approved the appointment of Mr. Sudhir Pendse as Non-Executive Independent Director (Additional Director) of the company to hold such office with effect from December 28, 2022 upto the date of the upcoming Annual/Extra Ordinary General Meeting of the Company. Mr. Pendse is a Commerce Graduate with Diploma in Exim Policies and Procedure . He also holds diploma in French language He has more than 30 years of experience in the field of Export Import, Exim logistics etc.; The company approved the resignation of Mr. Narendra Kumar Lodha as Non- Executive Non Independent Director with effect immediate effect., resignation of Mr. Chandrashekhar Joglekar as Non- Executive Non Independent Director of the Company with immediate effect.; resignation of Mr. Tanuj Kumar Lodha as Non- Executive Independent Director of the Company with immediate effect due to prior engagement and continuous travel.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 212% over the past three years.
Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: ₹4.35 (vs ₹1.43 in 2Q 2022)Second quarter 2023 results: EPS: ₹4.35 (up from ₹1.43 in 2Q 2022). Revenue: ₹935.8m (flat on 2Q 2022). Net income: ₹57.2m (up 204% from 2Q 2022). Profit margin: 6.1% (up from 2.0% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹163, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 263% over the past three years.
공시 • Oct 30Caprihans India Limited to Report Q2, 2023 Results on Nov 05, 2022Caprihans India Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 05, 2022
공시 • Oct 20Caprihans India Limited Announces Change in DirectorateCaprihans India Limited announced Resignation of Mr. Robin Banerjee, Managing Director: Mr. Robin Banerjee has resigned from position of the Managing Director of the Company vide his letter dated October 18, 2022 with effect from October 19, 2022. Mr. Shreyans Mohan Bhandari is appointed as Non-Executive Non-Independent Director of the Company to hold such office with effect from October 19, 2022 upto the date of the ensuing Annual/Extra Ordinary General Meeting of the Company.
Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non- Executive Independent Director Tanuj Lodha was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 11Caprihans India Limited Appoints Tanuj Lodha as A Non- Executive IndependentCaprihans India Limited appointed Tanuj Lodha as a Non- Executive Independent for period of 5 years with effect from May 03, 2022 upto May 02, 2027 at its AGM held on August 10, 2022. Mr. Tanuj Lodha aged 42, is an Advocate by profession and is a Senior Partner at Lodha & Lodha Advocates. Mr. Lodha is a Bachelor of Law (LLB), Chartered Accountant, MBA finance & marketing from the Indian School of Business. Mr. Lodha specializes in commercial laws including Arbitration, IBC, Real Estate & Company Laws. Mr. Lodha has represented several Corporates and other Persons in important matters and has appeared in several reported judgements' 'Mr. Lodha is an avid Golfer and actively participates in charitable causes.
공시 • Jul 28Caprihans India Limited to Report Q1, 2023 Results on Aug 05, 2022Caprihans India Limited announced that they will report Q1, 2023 results on Aug 05, 2022
Reported Earnings • Jul 20Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.93b (up 33% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year whereas the company’s share price has increased by 56% per year.
공시 • Jul 19Caprihans India Limited, Annual General Meeting, Aug 10, 2022Caprihans India Limited, Annual General Meeting, Aug 10, 2022, at 11:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022; to appoint a Director in place of Mr. Chandrashekhar Joglekar (DIN: 07265143); to appoint Mr. Tanuj Kumar Lodha (DIN: 06874388) as a Non-Executive, Independent Director of the Company; to ratify remuneration of Cost Auditors; and to reappoint Mr. Robin Banerjee (DIN 00008893) as Managing Director and payment of remuneration.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 148% over the past three years.
Reported Earnings • May 15Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.97b (up 35% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.2% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
공시 • May 07Caprihans India Limited to Report Fiscal Year 2022 Results on May 12, 2022Caprihans India Limited announced that they will report fiscal year 2022 results on May 12, 2022
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹136, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 132% over the past three years.
공시 • Mar 30Caprihans India Limited Announces Resignation of Anjali Seth as Independent DirectorCaprihans India Limited announced that Ms. Anjali Seth (DIN: 05234352), Independent Director, vide letter dated March 29, 2022, has tendered her resignation from the Board of the Company.
Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.84 (down from ₹4.31 in 3Q 2021). Revenue: ₹1.00b (up 38% from 3Q 2021). Net income: ₹50.4m (down 11% from 3Q 2021). Profit margin: 5.0% (down from 7.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
공시 • Feb 03Caprihans India Limited to Report Q3, 2022 Results on Feb 10, 2022Caprihans India Limited announced that they will report Q3, 2022 results on Feb 10, 2022
Board Change • Jan 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years.
Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS ₹1.43 (vs ₹3.71 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹943.3m (up 23% from 2Q 2021). Net income: ₹18.8m (down 61% from 2Q 2021). Profit margin: 2.0% (down from 6.3% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹151, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 95% over the past three years.
Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹3.83 (vs ₹1.77 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹851.6m (up 49% from 1Q 2021). Net income: ₹50.3m (up 117% from 1Q 2021). Profit margin: 5.9% (up from 4.1% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹15.40 (vs ₹7.00 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.04b (up 5.6% from FY 2020). Net income: ₹202.2m (up 120% from FY 2020). Profit margin: 6.6% (up from 3.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improved over the past weekAfter last week's 37% share price gain to ₹130, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 56% over the past three years.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹93.00, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 8.1% over the past three years.
공시 • Feb 04Caprihans India Limited to Report Q3, 2021 Results on Feb 10, 2021Caprihans India Limited announced that they will report Q3, 2021 results on Feb 10, 2021
공시 • Jan 22Caprihans India Limited Announces Sad Demise of K.V. Mani, Independent Director of the CompanyCaprihans India Limited announced the sad demise of Mr. K.V. Mani (DIN: 00533148), Independent Director of the Company on the night of January 20, 2021.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹87.30, the stock is trading at a trailing P/E ratio of 8.4x, up from the previous P/E ratio of 7x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 23%.
Is New 90 Day High Low • Dec 28New 90-day high: ₹84.40The company is up 56% from its price of ₹54.15 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.
Is New 90 Day High Low • Dec 08New 90-day high: ₹81.15The company is up 51% from its price of ₹53.75 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period.
Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 16% share price gain to ₹76.15, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.3x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.
Valuation Update With 7 Day Price Move • Nov 17Market bids up stock over the past weekAfter last week's 18% share price gain to ₹75.45, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.
Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS ₹3.71The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹819.3m (up 5.8% from 2Q 2020). Net income: ₹48.7m (up 205% from 2Q 2020). Profit margin: 5.9% (up from 2.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 09New 90-day high: ₹66.80The company is up 27% from its price of ₹52.50 on 11 August 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.
공시 • Sep 09+ 1 more updateCaprihans India Limited Announces Not to Recommend Any Dividend for Financial Year 2019-20Caprihans India Limited announced that in order to conserve financial resources owing to ongoing COVID-19 pandemic, the Board has not recommended any dividend for financial year 2019-20.
공시 • Aug 09Caprihans India Limited to Report Q1, 2021 Results on Aug 12, 2020Caprihans India Limited announced that they will report Q1, 2021 results on Aug 12, 2020
공시 • Jun 17Caprihans India Limited to Report Fiscal Year 2020 Results on Jun 19, 2020Caprihans India Limited announced that they will report fiscal year 2020 results on Jun 19, 2020